Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) generates a steady stream of news centered on its immuno-oncology pipeline, with particular focus on the botensilimab (BOT) and balstilimab (BAL) combination. As a Lexington, Massachusetts-based biological products manufacturer focused on cancer immunotherapy, the company’s updates frequently highlight progress in clinical trials, early-access frameworks and strategic collaborations.
Many recent headlines relate to BOT+BAL’s performance in advanced solid tumors. Agenus reports data from the C-800-01 Phase 1b trial, which evaluates the combination across multiple refractory cancers, and from the global BATTMAN CO.33 Phase 3 trial in microsatellite-stable colorectal cancer conducted with the Canadian Cancer Trials Group and international academic partners. News coverage also includes peer-reviewed publications, such as results in treatment-refractory ovarian cancer, and presentations at major oncology congresses.
Another major theme in Agenus news is patient access. The company has announced that France’s medicines agency authorized a national Autorisation d’Accès Compassionnel (AAC) protocol for BOT+BAL, enabling fully reimbursed hospital-based access for eligible patients with microsatellite-stable metastatic colorectal cancer, certain ovarian cancers and soft-tissue sarcomas. Additional stories describe named-patient and early-access programs in other geographies where regulations allow.
Strategic and corporate developments also feature prominently. Agenus has disclosed a collaboration with Zydus Lifesciences involving the sale of biologics manufacturing facilities in California, an equity investment in Agenus, and an exclusive license for BOT and BAL in India and Sri Lanka, along with the creation of Zylidac Bio LLC to house the acquired U.S. manufacturing assets. Investors following AGEN news can expect updates on clinical milestones, regulatory interactions, early-access expansions, manufacturing partnerships and periodic financial and corporate communications.
Agenus (NASDAQ: AGEN) announced its participation in the ASCO 2023 Annual Meeting from June 2-6 in Chicago, IL, where it will present clinical data from key trials. An oral presentation on June 5 will detail a Phase 2 trial of balstilimab and zalifrelimab combined with doxorubicin for advanced sarcomas. Additionally, a poster discussion on June 3 will cover the monotherapy results of AGEN2373, a CD137 agonist, in advanced solid tumors. Abstracts will be available on May 25. Balstilimab and zalifrelimab are designed to enhance immune response against cancer, while AGEN2373 targets T and NK cells with reduced liver toxicity risks.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will release its first-quarter 2023 financial results on May 9, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss results and corporate updates. The call can be accessed via dial-in or a live webcast from the Company’s events page. Agenus is focused on developing therapies that leverage the immune system for cancer treatment, utilizing various therapeutics, including antibody agents and cell therapies. The Company aims to expand the reach of cancer immunotherapy by pursuing a range of combination therapies. For more information, visit their website.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will feature Chairman and CEO Dr. Garo Armen at two upcoming investor conferences. The HC Wainwright BioConnect Investor Conference is set for May 2, 2023, at 3:30 PM ET in New York City, where Dr. Armen will participate in a fireside chat. Additionally, he will engage in 1x1 meetings at the EF Hutton Global Conference on May 10, 2023. A live webcast of the fireside chat will be available on the company’s website, with a replay posted afterward. Agenus aims to improve cancer treatment through innovative therapies that enhance the immune response. The company operates advanced antibody discovery platforms and a GMP manufacturing facility to support clinical programs.
Agenus Inc. (NASDAQ: AGEN) has received Fast Track Designation from the FDA for its combination therapy of botensilimab (AGEN1181) and balstilimab (AGEN2034) targeting non-MSI-H colorectal cancer patients. This designation is significant for heavily pretreated patients who have limited treatment options. The ongoing Phase 2 trial aims to show better effectiveness than current standards. Positive results from earlier trials revealed a 23% overall response rate and a 63% 12-month survival rate, significantly outperforming existing treatments. Dr. Steven O’Day highlighted the unmet medical need and the potential for Priority Review from the FDA. Moreover, the company is advancing research in various solid tumor indications.
Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
